Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 8:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo for testosterone Clear all
Completed Phase 3 Interventional

Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

NCT00338312
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, Placebo patch
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 28, 2026, 8:09 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin

NCT01686828
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen Deficiency, Metabolic Disease
Interventions
Acyline, Testosterone 1.62% gel, Letrozole, Placebo gel (for Testosterone 1.62% gel), Placebo pill (for Letrozole)
Drug
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 28, 2026, 8:09 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa

NCT00310791
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Hormone replacement therapy (estrogen/progestin), Placebo (Sugar Pill), Dehydroepiandrosterone (DHEA)
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
15 Years to 30 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Sep 28, 2026, 8:09 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

ITT-5 Mechanisms of Spermatogenesis in Man

NCT02147964
View directory record Official record
Conditions
Gonadotropin Deficiency
Interventions
Testosterone 1% Gel, Acyline, Dutasteride, Ketoconazole, HCG, placebo dutasteride, placebo ketoconazole
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 28, 2026, 8:09 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men

NCT01200862
View directory record Official record
Conditions
Obese Hypogonadotropic Hypogonadism
Interventions
Investigational new drug company code: BGS649, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
30 Years to 65 Years · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Tucson, Arizona • San Diego, California • Miramar, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 28, 2026, 8:09 PM EDT
Terminated Not applicable Interventional

Oxandrolone Rotator Cuff Trial

NCT03091075
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
Oxandrolone, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
40 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 28, 2026, 8:09 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary Syndrome

NCT00930228
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Flutamide, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 28, 2026, 8:09 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

NCT03767244
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, Androgen Deprivation Therapy (ADT), Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
44
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 28, 2026, 8:09 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone

NCT00839319
View directory record Official record
Conditions
Healthy Males
Interventions
Acyline, placebo hCG (no active ingredient), hCG (human chorionic gonadotropin), Testosterone gel
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Sep 28, 2026, 8:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cycled Testosterone Replacement Study

NCT00957528
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years to 85 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 28, 2026, 8:09 PM EDT
Completed Phase 4 Interventional

Effect of Testosterone Replacement on Insulin Resistance

NCT00487734
View directory record Official record
Conditions
Metabolic Syndrome, Hypogonadism
Interventions
Testosterone gel, Placebo for testosterone gel
Radiation · Drug
Lead sponsor
McGuire Research Institute
Other
Eligibility
20 Years to 65 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Sep 28, 2026, 8:09 PM EDT
Suspended Not applicable Interventional

Insulin Sensitivity in Men With the Metabolic Syndrome

NCT00433173
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
intravenous glucose tolerance test, testosterone, anastrozole, goserelin acetate implant, aerobic capacity (VO2 Max), MRI, muscle biopsy, measurement of resting metabolic rate (energy expenditure), Dual energy x-ray absorptiometry, Fasting oral glucose tolerance test
Procedure · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years to 75 Years · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 28, 2026, 8:09 PM EDT
Completed Phase 3 Interventional Results available

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

NCT01376349
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
prasterone, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
280
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Sep 28, 2026, 8:09 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

A Trial of Dehydroepiandrosterone (DHEA) Treatment for in Vitro Fertilization (IVF)

NCT00419913
View directory record Official record
Conditions
Infertility, Decreased Ovarian Reserve
Interventions
Dehydroepiandrosterone
Dietary Supplement
Lead sponsor
Center for Human Reproduction
Other
Eligibility
40 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Sep 28, 2026, 8:09 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

NCT02730169
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
BGS649, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Sep 28, 2026, 8:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Efficacy of Fenugreek Supplementation on Men's Health

NCT03528538
View directory record Official record
Conditions
Aging, Testosterone Deficiency
Interventions
AlphaFen fenugreek 400 mg, AlphaFen fenugreek 500 mg, Placebo
Dietary Supplement · Other
Lead sponsor
Jacksonville University
Other
Eligibility
21 Years to 45 Years · Male only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Sep 28, 2026, 8:09 PM EDT
Terminated Phase 2 Interventional Results available

Hypogonadism in Young Men With Type 2 Diabetes

NCT01155518
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Type 2 Diabetes
Interventions
testosterone, clomiphene, placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 28, 2026, 8:09 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause

NCT07408440
View directory record Official record
Conditions
Menopause, Sexual Dysfunction, Libido Disorder, Testosterone Deficiency
Interventions
Transdermal testosterone gel, Transdermal placebo gel
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 28, 2026, 8:09 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

ITT4 Intratesticular Hormonal Milieu in Man (ITT4)

NCT01215292
View directory record Official record
Conditions
Healthy Males
Interventions
Acyline, Testosterone gel, ketoconazole 400, Ketoconazole 800, Dutasteride, Anastrozole, Placebo ketoconazole
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Sep 28, 2026, 8:09 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study

NCT03142893
View directory record Official record
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill, Ganirelix, Dexamethasone, Dexamethasone Injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone, Hydrocortisone Injection, Gonadorelin, Corticorelin, Placebo oral capsule, Saline Solution, Saline Solution for Injection
Drug
Lead sponsor
Peter y. Liu
Other
Eligibility
22 Years to 45 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 28, 2026, 8:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

NCT02513940
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Testosterone, Progesterone, Placebo, Ibutilide
Drug
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 28, 2026, 8:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility of an Oral Intervention for Sexual Health in Transgender Men

NCT06470906
View directory record Official record
Conditions
Vaginal Dysbiosis, Vaginal Disease, Molecular-bacterial Vaginosis
Interventions
Probiotic Group, Placebo Group
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 28, 2026, 8:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening

NCT04675788
View directory record Official record
Conditions
Long QT Syndrome, Abnormalities, Drug-Induced
Interventions
Progesterone, Ibutilide, Testosterone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
50 Years to 99 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 28, 2026, 8:09 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

NCT00203996
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions
continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp
Device · Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 28, 2026, 8:09 PM EDT